Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351545 · ClinicalTrials.gov registry record
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A clinical trial of Hematologic Malignancies and Acute Lymphoblastic Leukemia (ALL), sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- 99,999
- Enrollment target
- 20
- Study locations
NCT01351545 is a study of Hematologic Malignancies and Acute Lymphoblastic Leukemia (ALL) that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 99,999 participants, above the 490-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (20308% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01351545, a study of Hematologic Malignancies and Acute Lymphoblastic Leukemia (ALL), is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- 99,999 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Conditions Studied
Interventions
- DRUG A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Study Locations (20)
California
- City of Hope - Duarte
- Children's Hospital of Los Angeles - Glendale
- Scripps Green Hospital - La Jolla
- University of California San Diego - La Jolla
- Loma Linda University Cancer Center - Loma Linda
- UCLA - Los Angeles
- Children's Hospital and Research Center of Oakland - Oakland
- Children's Hospital of Orange County (CHOC) - Orange
- Sutter Medical Center - Sacramento
- Rady Children's Hospital San Diego - San Diego
- UCSF (adults) - San Francisco
- UCSF (Peds) - San Francisco
- Stanford University Medical Center - Stanford
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Phoenix Children's Hospital - Phoenix
- Mayo Clinic Arizona (adults) - Phoenix
- University of Arizona Medical Center - Tucson - Tucson
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,999 participants |
| Start Date | 2011-10 |
| Est. Completion | 2041-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01351545
The ClinicalTrials.gov registry entry for NCT01351545 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 99,999 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 490-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (20308% higher). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) is the first listed.
NCT01351545 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01351545 about?
NCT01351545 is a clinical study titled "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)". This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
What is the current status of trial NCT01351545?
This trial is currently recruiting. The enrollment target is 99,999 participants. The study started on 2011-10. Estimated completion is 2041-10.
What conditions does trial NCT01351545 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Histiocytic Disorders, Inherited Disorders of Metabolism.
What interventions are being tested in trial NCT01351545?
The interventions under investigation include: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) (DRUG).
Who is sponsoring clinical trial NCT01351545?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01351545 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.